Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands
Authors' conclusion
This study suggests that low survivin expression is predictive of resistance to fg-SRL in somatotropinomas, but not of tumor invasiveness.
Study context
- Population
- Somatotropinoma samples (tissue microarrays); drug resistance evaluated in patients who received somatostatin receptor ligand (SRL) treatment34 SRL-treated
- Participants
- 52 somatotropinoma samples
- Exposure
- SRL-resistant vs responsive somatotropinomas; invasive vs non-invasive
- Outcome
- Factors associated with resistance to fg-SRL
Methodological detailstissue microarrays, immunohistochemistry
- Tissue microarrays
- Immunohistochemistry
Main finding
As reported in the abstract
- Low survivin expression associated with first-generation SRL (fg-SRL) resistance
- P = 0.04
- Hyperintense T2 weighted image (T2WI) signal associated with fg-SRL resistance
- P = 0.01
- Younger age associated with fg-SRL resistance
- P = 0.01
- Sparsely granular adenomas (SGA) associated with fg-SRL resistance
- P = 0.04
- High postoperative growth hormone (GH) associated with fg-SRL resistance
- P = 0.049
- High postoperative IGF-1 associated with fg-SRL resistance
- P < 0.001
- Large postoperative tumor size associated with fg-SRL resistance
- P = 0.02
Observational data: associations, not effects.
Further findings
Markers associated with SGA
- Low survivin expression associated with SGA
- P = 0.04
- Low SSTR2 expression associated with SGA
- P = 0.01
- High 4EBP1 expression associated with SGA
- P = 0.001
Factors associated with tumor invasiveness
- Younger age
- P = 0.03
- Large preoperative tumor
- P = 0.04
- Large postoperative tumor
- P = 0.006
- Low SSTR2 expression
- P = 0.03
- High baseline GH
- P = 0.01
- High baseline IGF-1
- P = 0.02
- Survivin, 4EBP1, Ki-67 and granulation patterns not associated with tumor invasion
Original publication
Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands. J Clin Endocrinol Metab. Published 24 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →